Diseases and injuries were organised into a levelled cause hierarchy from the three broadest causes of death and disability at Level 1 to the most specific causes at Level 4. Within the three Level 1 causes—communicable, maternal, neonatal, and nutritional diseases; non-communicable diseases; and injuries—there are 22 Level 2 causes, 174 Level 3 causes, and 301 Level 4 causes (including 131 Level 3 causes that are not further disaggregated at Level 4; see
Sarcoma
Sarcomas can occur in any part of the body and are categorized based on the specific cell type and tissue of origin.
These cancers often present diagnostic and treatment challenges, making research and innovation in this field crucial.
Identifying the best protocols and optimizing research approaches can help accelerate progress in sarcoma undertsanding and care.
Most cited protocols related to «Sarcoma»
Diseases and injuries were organised into a levelled cause hierarchy from the three broadest causes of death and disability at Level 1 to the most specific causes at Level 4. Within the three Level 1 causes—communicable, maternal, neonatal, and nutritional diseases; non-communicable diseases; and injuries—there are 22 Level 2 causes, 174 Level 3 causes, and 301 Level 4 causes (including 131 Level 3 causes that are not further disaggregated at Level 4; see
Most recents protocols related to «Sarcoma»
Example 7
Five groups including tucaresol, tucaresol plus PD-1 or PD-L1 antibody, tucaresol plus CTLA-4 antibody, CTLA-4 antibody plus PD-1 or PD-L1 antibody, and tucaresol plus plinabulin are tested to determine their effect in an animal xenograft model.
The combined treatment with tucaresol and the checkpoint inhibitor(s) is tested in comparison with the treatment with tucaresol alone, the treatment with checkpoint inhibitor alone, or combination of checkpoint inhibitors. The tests are performed using seven to ten-week old athymic (nu/nu) mice that were injected subcutaneously with human tumor cell lines (of either solid or liquid tumor origin, for example of breast, lung, colon, brain, liver, leukemia, myeloma, lymphoma, sarcoma, pancreatic or renal origin). Six to ten testing groups are prepared, and each group includes 10 mice.
Each treatment starts at tumor size between 40-150 mm3 and continues until Day 24-56, when the animals are necropsied. To determine the efficacy of each treatment, the following data are collected: mortality; the body weight of the mice assessed twice weekly both prior to treatments; the rate of tumor growth as determined by the tumor size measurement (twice every week); the tumor growth index; overall survival rate; the tumor weight at necropsy; and the time required to increase tumor size 10 fold.
The sampling followed a relatively standardized protocol for all TBI cases: samples were collected from the cortex and underlying white matter of the pre-frontal gyrus, superior and middle frontal gyri, temporal pole, parietal and occipital lobes, deep frontal white matter, hippocampus, anterior and posterior corpus callosum with the cingula, lenticular nucleus, thalamus with the posterior limb of the internal capsule, midbrain, pons, medulla, cerebellar cortex and dentate nucleus. In some cases, gross pathology (e.g. contusions) mandated further sampling along with the dura and spinal cord if available. The number of available sections for these three cases was 26 for case1, and 24 for cases 2 and 3.
For the detection of ballooned neurons, all HE or HPS sections, including contusions, were screened at 200×.
Representative sections were stained with either hematoxylin–eosin (HE) or hematoxylin-phloxin-saffron (HPS). The following histochemical stains were used: iron, Luxol-periodic acid Schiff (Luxol-PAS) and Bielschowsky. The following antibodies were used for immunohistochemistry: glial fibrillary acidic protein (GFAP) (Leica, PA0026,ready to use), CD-68 (Leica, PA0073, ready to use), neurofilament 200 (NF200) (Leica, PA371, ready to use), beta-amyloid precursor-protein (β-APP) (Chemicon/Millipore, MAB348, 1/5000), αB-crystallin (EMD Millipore, MABN2552 1/1000), ubiquitin (Vector, 1/400), β-amyloid (Dako/Agilent, 1/100), tau protein (Thermo/Fisher, MN1020 1/2500), synaptophysin (Dako/Agilent, ready to use), TAR DNA binding protein 43 (TDP-43) ((Protein Tech, 10,782-2AP, 1/50), fused in sarcoma binding protein (FUS) (Protein tech, 60,160–1-1 g, 1/100), and p62 (BD Transduc, 1/25). In our index cases, the following were used for the evaluation of TAI: β-APP, GFAP, CD68 and NF200; for the neurodegenerative changes: αB-crystallin, NF200, ubiquitin, tau protein, synaptophysin, TDP-43, FUS were used.
For the characterization of the ballooned neurons only, two cases of fronto-temporal lobar degeneration, FTLD-Tau, were used as controls. One was a female aged 72 who presented with speech difficulties followed by neurocognitive decline and eye movement abnormalities raising the possibility of Richardson’s disorder. The other was a male aged 67 who presented with a primary non-fluent aphasia progressing to fronto-temporal demαentia. In both cases, the morphological findings were characteristic of a corticobasal degeneration.
For the primary analysis of PFS, the respective HRs of arms A to B and A to C will be calculated using an unstratified Cox proportional-hazards model for all enrolled patients, and the treatment with the best HR will be judged to be the most promising regimen. Since this study does not make judgments based on hypothesis testing, no significance level is set a priori, and no adjustment will be made for multiplicity.
Subgroup analyses based on the factors mentioned below are to be conducted, as necessary. The factors for which subgroup analyses are planned include age group 1 (< 40/ ≥ 40 years), age group 2 (< 70/ ≥ 70 years), sex (male/female), PS (0/1 and 2), histological type (liposarcoma/leiomyosarcoma/translocation-related sarcoma/other), distant metastasis 1 [(M1 and/or N1)/other], distant metastasis 2 [M1/(N1 and M0)/other], and doxorubicin (perioperative chemotherapy/palliative chemotherapy).
University Institute of Oncology. The inclusion criteria were an age of ≥65
years, diagnosis of soft tissue sarcoma, and follow-up or treatment for soft
tissue sarcoma. Patients aged <65 years, patients with bone and cartilage
tumors, and patients who had discontinued follow-up were not included in the
study. The files of patients from January 2000 to December 2020 were examined,
and patients who were deemed suitable for the study were included.
2. Endometrioid adenocarcinoma combined with other histological types
3. Non-endometrial carcinoma, for example, serous carcinoma, clear cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, or uterine sarcoma (including carcinosarcoma)
4. An interval between the operation and the start of adjuvant therapy exceeding 8 weeks
5. Previous pelvic radiotherapy
6. Previous history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
7. History of myocardial infarction, stroke, unstable angina, decompensated heart failure, or deep vein thrombosis
8. Impaired renal or cardiac function.
9. Known intolerance to intervention therapy or any excipients
10. Known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study.
Top products related to «Sarcoma»
More about "Sarcoma"
These cancers can occur in any part of the body and are categorized based on the specific cell type and tissue of origin.
Sarcomas often present diagnostic and treatment challenges, making research and innovation in this field crucial.
Identifying the best protocols and optimizing research approaches can help accelerate progress in sarcoma understanding and care.
Commonly used cell culture media like DMEM, RPMI 1640, and supplements such as L-glutamine, penicillin, and streptomycin are essential for sarcoma research.
Techniques like 3D cell culture using MSTO-211H cells can provide more relevant models for studying sarcoma biology and evaluating potential therapies.
Advances in sarcoma research, including the development of AI-powered tools like PubCompare.ai, are revolutionizing the field.
These innovative solutions enable researchers to easily locate the best protocols from literature, preprints, and patents through intelligent comparisons, helping to accelerate progress in sarcoma understanding and care.